Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults.

Next Previous
X
Search
Trial Profile

Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HBV 002 (Primary) ; Aluminium hydroxide
  • Indications West Nile virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Hawaii Biotech

    • Most Recent Events

    • 17 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2009 Results reported in a Hawaii Biotech media release.
    • 16 Dec 2008 Preliminary safety results and immunologic data will be available early in 2009; complete results are expected by the third quarter 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top